Novolog Pharm Up 1966 Stock Return On Equity
| NVLG Stock | 169.90 0.50 0.30% |
Novolog Pharm Up 1966 fundamentals help investors to digest information that contributes to Novolog Pharm's financial success or failures. It also enables traders to predict the movement of Novolog Stock. The fundamental analysis module provides a way to measure Novolog Pharm's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novolog Pharm stock.
Novolog |
Novolog Pharm Up 1966 Company Return On Equity Analysis
Novolog Pharm's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Novolog Pharm Return On Equity | 0.11 |
Most of Novolog Pharm's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novolog Pharm Up 1966 is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Novolog Pharm Up 1966 has a Return On Equity of 0.106. This is 100.44% lower than that of the Health Care Providers & Services sector and 107.46% lower than that of the Health Care industry. The return on equity for all Israel stocks is 134.19% lower than that of the firm.
Novolog Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novolog Pharm's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Novolog Pharm could also be used in its relative valuation, which is a method of valuing Novolog Pharm by comparing valuation metrics of similar companies.Novolog Pharm is currently under evaluation in return on equity category among its peers.
Novolog Fundamentals
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0174 | |||
| Profit Margin | 0.03 % | |||
| Operating Margin | 0.05 % | |||
| Current Valuation | 1.45 B | |||
| Shares Outstanding | 508.7 M | |||
| Shares Owned By Insiders | 42.45 % | |||
| Shares Owned By Institutions | 40.71 % | |||
| Price To Book | 3.24 X | |||
| Price To Sales | 0.99 X | |||
| Revenue | 1.26 B | |||
| Gross Profit | 154.67 M | |||
| EBITDA | 115.92 M | |||
| Net Income | 42.32 M | |||
| Cash And Equivalents | 107.97 M | |||
| Cash Per Share | 0.31 X | |||
| Total Debt | 916 K | |||
| Debt To Equity | 0.60 % | |||
| Current Ratio | 0.96 X | |||
| Book Value Per Share | 0.86 X | |||
| Cash Flow From Operations | 83.39 M | |||
| Earnings Per Share | 0.08 X | |||
| Target Price | 2.1 | |||
| Number Of Employees | 900 | |||
| Beta | 0.2 | |||
| Market Capitalization | 1.09 B | |||
| Total Asset | 2.29 B | |||
| Annual Yield | 0.03 % | |||
| Net Asset | 2.29 B | |||
| Last Dividend Paid | 0.063 |
About Novolog Pharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novolog Pharm Up 1966's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novolog Pharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novolog Pharm Up 1966 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Novolog Stock
Novolog Pharm financial ratios help investors to determine whether Novolog Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Novolog with respect to the benefits of owning Novolog Pharm security.